Saniona AB, of Ballerup, Denmark, said it started a phase IIa study in the Czech Republic and Hungary for Tesomet in patients with Prader-Willi syndrome (PWS), having randomized the first three patients to either receive the drug, a combination of tesofensine 0.5 mg plus metoprolol 50 mg daily, or placebo.